Inbio Ventures

Inbio Ventures concentrates on early-stage biotechnology companies, typically entering at the seed or Series A phase. The firm provides institutional capital to advance preclinical programs toward proof-of-concept milestones. This capital bridges the gap between grant-funded academic research and larger venture rounds.

Based on public record and the firm's stated life-science focus, Inbio Ventures invests across biotechnology platforms including oncology therapeutics, precision medicine diagnostics, and enabling drug-development tools. The firm draws from Russia's academic pipeline in molecular biology, immunology, and genetic research.

The firm sources opportunities through deep relationships within Russia's state-supported research institutes, particularly in Moscow, St. Petersburg, and Novosibirsk. This academic-embedded model grants visibility into laboratory-stage programs that are rarely marketed to international venture capital. Its scientist-founder network operates as a proprietary sourcing channel within a market that has limited cross-border biotech investment activity.

Inbio Ventures takes direct equity positions and often leads early-stage rounds, though it also co-invests alongside other specialist scientific funds active in the Russian biotech ecosystem. Its structure allows it to act as the primary institutional investor for preclinical and seed-stage companies emerging from academic labs.

The firm concentrates on Russia's three principal biotechnology clusters — Moscow, St. Petersburg, and Novosibirsk — with select exposure to technology spun out from academic centers elsewhere in the CIS region. This domestic geographic footprint reflects the sourcing model's dependence on local institutional trust and language-specific researcher relationships.